PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Despite the significant achievements in the diagnosis and treatment of metastatic breast cancer (MBC), this condition remains substantially an incurable disease. In recent years, several clinical studies have aimed to identify novel molecular targets, therapeutic strategies, and predictive biomarker...

Full description

Bibliographic Details
Main Authors: Nicola Fusco, Umberto Malapelle, Matteo Fassan, Caterina Marchiò, Simonetta Buglioni, Simonetta Zupo, Carmen Criscitiello, Paolo Vigneri, Angelo Paolo Dei Tos, Eugenio Maiorano, Giuseppe Viale
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
breast cancer
biomarkers
PIK3CA
targeted therapy
HR+/HER2-
RT-PCR
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.644737/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.644737/full

Similar Items